Compare SPDR Gold Trust (GLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs State Street SPDR S&P Biotech ETF — how do they compare? SPDR Gold Trust trades at $383.71 (market cap $139.66B), while State Street SPDR S&P Biotech ETF trades at $153.61 (market cap $10.11B). The key difference: SPDR Gold Trust is far larger — about 13.8× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| GLD | XBI | |
|---|---|---|
Market Cap | $139.66B | $10.11B |
Volume | 9,544,773 | 12,903,266 |
52-Week High | $495.90 | $169.55 |
52-Week Low | $362.32 | $104.99 |
Typical Hold Time | 74 Days | 37 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, is trading at $384.45 with a 2.28% daily gain, though technical indicators signal bearish momentum with 17 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and a strong U.S. dollar, as highlighted in recent financial news. Key support levels are at $373-$377, while resistance sits at $380-$384. Recent market sentiment remains cautious amid Federal Reserve policy uncertainty and inflation concerns.
The outlook for GLD is mixed, with near-term headwinds from monetary policy and currency strength potentially limiting upside. However, gold's role as a hedge against inflation and global debt concerns offers long-term diversification benefits. Risks include further rate hikes and dollar appreciation, but tactical buying opportunities may emerge if support levels hold.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
